Abstract

Dysregulation of forkhead box D1 (FOXD1) is known to promote tumor progression; however, its molecular mechanism of action is unclear. Based on microarray analysis, we identified galectin-3/LGALS3 (Gal-3) as a potential downstream target of FOXD1, as FOXD1 transactivated Gal-3 by interacting with the Gal-3 promoter to upregulate Gal-3 in FOXD1-overexpressing CL1-0 lung cancer cells. Ectopic expression of FOXD1 increased the expression of Gal-3 and the growth and motility of lung cancer cells, whereas depletion of Gal-3 attenuated FOXD1-mediated tumorigenesis. ERK1/2 interacted with FOXD1 in the cytosol and translocated FOXD1 into the nucleus to activate Gal-3. Gal-3 in turn upregulated FOXD1 via the transcription factor proto-oncogene 1 (ETS-1) to transactivate FOXD1. The increase in ETS-1/FOXD1 expression by Gal-3 was through Gal-3-mediated integrin-β1 (ITGβ1) signaling. The overexpression of both FOXD1 and Gal-3 form a positive regulatory loop to promote lung cancer aggressiveness. Moreover, both FOXD1 and Gal-3 were positively correlated in human lung cancer tissues. Our findings demonstrated that FOXD1 and Gal-3 form a positive feedback loop in lung cancer, and interference of this loop may serve as an effective therapeutic target for the treatment of lung cancers, particularly those related to dysregulation of Gal-3.

Highlights

  • Lung cancer is one of the most prevalent cancers worldwide [1]

  • To identify novel downstream molecules involved in forkhead box D1 (FOXD1)-mediated lung cancer aggressiveness, FOXD1 cDNA was overexpressed in cells or knocked down by specific siRNA, and mRNA microarrays and comparative gene expression analyses were performed

  • We found that a high level of FOXD1

Read more

Summary

Introduction

Lung cancer is one of the most prevalent cancers worldwide [1]. 80% of lung cancers are non-small cell lung cancers (NSCLCs) [2]. Chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy are the current standard treatments. Patients with advanced lung cancer have 10–15% overall 5-year survival rates, an median overall survival (OS) of about. 11.1 months, and a post-recurrence survival rate (PRS) of 13% (hazard ratio (HR) = 0.78) [2,3,4]. Even with second-line drug treatment, such as nivolumab, progression-free survival (PFS) is about. It is critical to elucidate the molecular mechanisms of lung cancer proliferation and metastasis to identify and develop novel therapeutic targets in lung cancer

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call